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Abstract
Objective—Farletuzumab is a humanized monoclonal antibody that binds to folate receptor 
alpha, over-expressed in epithelial ovarian cancer (EOC) but largely absent in normal tissue. 
Previously, carboplatin plus pegylated liposomal doxorubicin showed superior progression-free 
survival and an improved therapeutic index compared with carboplatin/paclitaxel in relapsed 
platinum-sensitive EOC. This study assessed safety of farletuzumab/carboplatin/pegylated 
liposomal doxorubicin in women with platinum-sensitive recurrent EOC.
Methods—This multicenter, single-arm study enrolled patients with platinum-sensitive EOC in 
first or second relapse for treatment with weekly farletuzumab 2.5 mg/kg plus carboplatin AUC5–6 
and pegylated liposomal doxorubicin 30 mg/m2 every 4 weeks for 6 cycles. Subsequently, 
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maintenance with single-agent farletuzumab 2.5 mg/kg once weekly or farletuzumab 7.5 mg/kg 
once every three weeks continued until progression. The primary objective was to assess the safety 
of farletuzumab/carboplatin/pegylated liposomal doxorubicin.
Results—Fifteen patients received a median of 12.0 cycles (range, 3–26) of farletuzumab as 
combination therapy or maintenance, for a median of 45.0 weeks (range 9–95). Farletuzumab/
carboplatin/pegylated liposomal doxorubicin was generally well tolerated, with no farletuzumab-
related grades 3–4 adverse events. The most commonly reported adverse events were associated 
with combination chemotherapy: fatigue (73.3%), nausea (46.7%), and neutropenia (40%). Ten 
patients had grade ≥3 adverse events, most frequently neutropenia and fatigue. No cardiac toxicity 
was seen. Best overall responses (RECIST) were a complete response for one patient, partial 
responses for 10 patients, and stable disease for four patients.
Conclusions—Farletuzumab plus carboplatin/pegylated liposomal doxorubicin in women with 
platinum-sensitive EOC demonstrated a safety profile consistent with that of carboplatin plus 
pegylated liposomal doxorubicin.
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1. Introduction
Farletuzumab (FAR) is a humanized monoclonal antibody that binds to folate receptor 
alpha, known to be overexpressed in epithelial ovarian cancer (EOC) but largely absent in 
normal tissue [1–4]. In preclinical studies, FAR has exhibited immune-effector mediated 
effects via antibody-dependent cell cytotoxicity (ADCC) and complement-dependent 
cytotoxicity, and single-agent anti-tumor activity in xenograft models of ovarian cancer, as 
well as synergistic effects with chemotherapeutic agents [5,6]. The combination of 
carboplatin and paclitaxel has long been utilized as a preferred treatment regimen for 
platinum-sensitive EOC. This regimen was used in a Phase 2 study of FAR in patients with 
EOC who had experienced first relapse, with the combination of carboplatin/paclitaxel/FAR 
found to be active as well as well tolerated [7]. Recent studies have shown that FAR 
enhances type 2 cell death in tumor cells and that the combination of combination of these 
immune-effector cellular signaling pathway most likely result in tumor growth suppression 
and toxicity [8].
Recent studies have suggested that the combination of carboplatin and pegylated liposomal 
doxorubicin (PLD) may be the preferred regimen than carboplatin/paclitaxel for platinum-
sensitive recurrent EOC [9–11]. In a randomized Phase 3 noninferiority study [9] of 
carboplatin plus PLD versus carboplatin plus paclitaxel in relapsed platinum-sensitive 
ovarian cancer, the carboplatin/PLD combination demonstrated noninferiority with the 
comparator in terms of progression-free survival (PFS) (11.3 months versus 9.4 months; P = 
0.005) and lower rates of severe and long-lasting neuropathy. The benefit of 
carboplatin/PLD over carboplatin/paclitaxel was noted to persist in analysis of patients who 
relapsed between 6 and 12 and 6–24 months [11,12]. Toxicities were more common with 
carboplatin/paclitaxel and included neutropenia, neuropathy, and hypersensitivity reactions. 
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Interestingly, carboplatin/PLD was associated with a substantially reduced incidence of 
platinum-associated hypersensitivity reactions in this study. It should be noted that the safety 
profile of FAR consists of infrequent and mild drug hypersensitivity adverse events (AEs) 
and rare interstitial pulmonary changes. No adverse interaction with chemotherapy was 
expected.
In view of a recent increase in the use of carboplatin plus PLD in patients with platinum-
sensitive EOC, a Phase 1b study of FAR plus carboplatin and PLD was undertaken to assess 
the safety of this triple-agent combination in this disease context.
2. Methods
2.1. Study population
Each participant provided written informed consent before initiating study procedures. All 
enrolled patients were greater than 18 years old and had histologically- or cytologically-
confirmed, platinum-sensitive EOC (including primary peritoneal or fallopian tube 
malignancies) with relapse as defined by Gynecologic Cancer InterGroup (GCIG) CA-125 
criteria or protocol-specific modified (to reflect current practices in the medical oncology 
community and nuances specific to ovarian cancer) Response Evaluation Criteria in Solid 
Tumors (RECIST) v.1.0 for 6 months or longer after completion of first- or second-line 
platinum chemotherapy. All had a Karnofsky Performance Status at least 70%. Patients were 
required to have the following laboratory and clinical results within two weeks prior to study 
day 1: absolute neutrophil count (ANC) ≥1.5 × 109 cells/L; platelet count ≥100 × 109 
cells/L; hemoglobin ≥9 g/dL; creatinine ≤1.5 × upper limit of normal (ULN); bilirubin ≤ 1.5 
× ULN; aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline 
phosphatase (ALK-P) <2.5 × ULN.
Women with known central nervous system (CNS) tumor involvement, other active 
malignancy, clinically significant cardiac disease, active serious systemic disease or 
infection, evidence of immune or allergic reaction or documented antidrug antibodies 
(ADAs) after prior monoclonal antibody therapy were excluded from participation.
2.2. Study design and treatment
This was a multicenter, open-label Phase 1b study with 2.5 mg/kg intravenous (IV) FAR in 
combination with carboplatin and PLD to assess the safety of this drug regimen in patients 
with platinum-sensitive EOC. The primary objective of this study was to assess the safety of 
FAR/carboplatin/PLD in this patient population. Hematology, clinical chemistries, urine, 
and left ventricular ejection fraction (LVEF) were monitored on Day 1, Week 1 of every 4-
week cycle. Tumor assessment (using RECIST v.1.0) was performed every other cycle. 
Secondary objectives included assessment of response and PFS and the pharmacokinetic 
effect of FAR on chemotherapy (not reported here).
Study patients received carboplatin AUC5–6 IV and PLD 30 mg/m2 IV on Day 1 of an every 
4-week combination treatment cycle. An ANC of 1.5 × 109 cells/L was required for 
retreatment with chemotherapy. If toxicity due to carboplatin or PLD occurred, doses could 
be reduced or delayed according to institutional guidelines. If chemotherapy was 
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discontinued without disease progression, the investigator could elect to continue the patient 
on single-agent FAR until disease progression. Following completion of approximately 6 
cycles with FAR/carboplatin/PLD therapy, patients who had not progressed began 
maintenance treatment with single-agent FAR 2.5 mg/kg once weekly in 4-week cycles until 
disease progression. A protocol amendment based on new pharmacokinetic data 
subsequently changed the maintenance therapy administration to single-agent FAR 7.5 
mg/kg once every three weeks. Disease response and progression free survival was assessed 
utilizing modified RECIST v1.0 based upon computed tomography (CT) scan or magnetic 
resonance imaging (MRI) findings and by CA-125 levels (i.e., CA-125 ≥ 2 × upper limit of 
normal documented on 2 occasions).
All patients were premedicated prior to FAR infusion with acetaminophen 650 mg by mouth 
and, optionally, diphenhydramine 25 mg to 50 mg IV or equivalent per clinic routine. In the 
event of a drug hypersensitivity reaction believed to be associated with FAR, patients were 
premedicated for subsequent infusions with antipyretic and histamine receptor blocking 
medications per clinic routine. Prophylactic antiemetics were used for carboplatin and PLD 
according to usual practice at each site.
All documents pertaining to study design, informed consent, and patient information 
received Institutional Review Board approval in accordance with the Declaration of Helsinki 
before the study began.
2.3. Safety and efficacy evaluations
Safety assessments consisted of monitoring and recording all AEs and serious AEs; 
performance of history and physical examinations; regular monitoring of hematology, blood 
chemistry, and urine laboratory values (prior to treatment on Day 1, Week 1 of cycle 1); and 
monitoring with ECHO or MUGA at baseline and every third cycle during combination 
therapy, then every fourth cycle during maintenance therapy.
Efficacy evaluations by modified RECIST v1.0 were performed at screening, every second 
cycle during combination treatment, every third cycle during maintenance, and at the study 
exit visit. Patients who discontinued prior to disease progression for any other reason (e.g., 
intolerable AE) were followed radiographically until documented disease progression or 
initiation of a new anticancer treatment occurred. As feasible, follow-up scans were obtained 
every 3 months; CT or MRI scans were read locally.
2.4. Anti-drug antibodies
Patients were monitored for the presence of ADA at screening, Day 1 of each combination 
treatment cycle, Day 1 of every third once-weekly maintenance cycle (or every other 
maintenance cycle during FAR dosing every 3 weeks), study exit visit, and 30 days post 
final dose. Associated FAR serum concentration and occurrence of a drug hypersensitivity 
AE at the time of a positive ADA were identified. The validated assay used for ADA 
analysis was estimated at 0.5 ng/mL based on detection of a FAR-specific monoclonal IgG 
positive control used as a surrogate ADA; the sensitivity was well below the FDA minimum 
expected concentration of 250–500 ng/mL [13].
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2.5. Statistical analysis
The target sample size for this study was 15 patients. The sample size for this study, 15 
patients, was determined to be sufficient to adequately address the primary objective. No 
statistical comparisons were performed that would require a minimum sample size for the 
study.
Safety analyses were performed on all patients who received at least one dose of 
combination treatment. Safety data were summarized using descriptive statistics. For overall 
response and CA-125 response, the number (percentage) of patients who responded was 
obtained and an exact 2-sided 95% confidence interval (CI) was constructed based on 
Clopper-Pearson methodology [14]. For PFS, duration of response, and time to response, the 
median was estimated using Kaplan-Meier methodology [15]. The 2-sided 95% CI for the 
median was constructed using the methodology of Brookmeyer and Crowley [16]. Two-
sided 95% CIs for estimates of these endpoints at selected time points were calculated using 
the log-log transformation [17].
3. Results
3.1. Patient disposition
This study was conducted at three centers in the United States between 18 May 2010 and 14 
Aug. 2012. Fifteen patients were enrolled and received at least one dose of FAR (Fig. 1). 
Carboplatin was dosed at AUC5 in 8 patients and AUC6 in 7 patients. Patient demographics 
and baseline characteristics are presented in Table 1. The median age was 62.0 years (range 
47–82). All patients were Caucasian. All but one patient (with fallopian tube cancer) had a 
primary diagnosis of ovarian cancer.
3.2. Safety
Fifteen patients received a median of 12.0 cycles (range, 3–6) of FAR as a component of 
combination therapy or as maintenance monotherapy, 6 cycles (range, 3–9) during 
combination therapy and 6 cycles (range, 3–26) during maintenance. The median length of 
exposure to FAR was 45 weeks (range 9–95 weeks). Table 2 presents all related AEs that 
occurred in more than one patient. During combination treatment, the most common AEs 
were fatigue (73.3%), nausea (46.7%), and neutropenia (40%). For single-agent maintenance 
(once weekly), the most common AEs were peripheral edema (16.7%) and cough (16.7%). 
During single-agent maintenance (once every three weeks), the most common AE was 
urinary tract infection (25%). Ten patients on combination treatment reported Grade 3 or 
higher AEs, the most common being neutropenia (5 patients) and fatigue (2 patients). One 
patient experienced Grade 3 palmar-plantar erythrodysesthesia (PPE). Six patients (40%) 
experienced AEs that interrupted or delayed the administration of chemotherapy. The most 
frequent AEs that delayed or interrupted chemotherapy were neutropenia and PPE.
All 15 patients who received combination treatment reported 103 chemotherapy-related 
AEs. The most frequently reported chemotherapy-related AEs were fatigue (66.7%), 
neutropenia (40%), nausea (33.3%), PPE (33.3%), rash (33.3%), and alopecia (26.7%). 
These percentages were comparable to those seen with carboplatin/PLD only. Two patients 
Kim et al. Page 5
Gynecol Oncol. Author manuscript; available in PMC 2016 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(13.3%) experienced 2 drug hypersensitivity AEs, hyperhidrosis and pruritus. Because of the 
development of ADAs, these were considered FAR related. Both events occurred during 
combination treatment. Three of the 15 patients (20%) receiving FAR/carboplatin/PLD 
reported 11 AEs that were considered (investigator judgment) related to FAR, the most 
frequent being constipation and fatigue (2 patients each [13.3%]); during maintenance, there 
were no AEs considered at least possibly related to FAR.
Four patients reported serious AEs during combination treatment, two with small bowel 
obstructions and one each with febrile neutropenia and venous thrombosis. One patient 
experienced 3 serious AEs of small bowel obstruction that were considered per investigator 
judgment to be related to chemotherapy. None of the reported serious events was related to 
FAR. Four of 15 patients (26.7%) tested positive for ADA at least once while on study. 
Potential immunogenic reactions to FAR occurred in two patients, one with grade 2 
hyperdyrosis and one with grade 1 pruritus. Seven patients (46.7%) experienced Grade 3 
laboratory abnormalities while receiving FAR/carboplatin/PLD: 6 patients with decreased 
neutrophils, one with increased alanine aminotransferase, and one with decreased white 
blood cell count. One patient experienced a Grade 3 increase in glucose while receiving 
maintenance treatment. No drug-induced liver events were identified. No cardiac toxicity, 
defined as a ≥ 15% decrease in LVEF from baseline or ≥5% from institutional lower limit of 
normal, was observed during chemotherapy or during FAR maintenance. All but 3 patients 
had the same LVEF at last study assessment as they had at screening. Three clinically not 
significant decreases were noted (14%, 10%, 27%); overall, the lowest value noted remained 
above the upper limit of normal for the site.
No patient discontinued treatment during the study for any reason other than disease 
progression, and no on-study deaths were reported.
3.3. Antitumor activity
Median radiologic PFS was 10.4 months (range 9.3–15.5); median CA-125 PFS was 17.7 
months (range 11.1–20.3). Best overall responses by RECIST were a complete response for 
one patient, partial responses for 10 patients, and stable disease for four patients. Median 
duration of radiologic response was 8.4 months (range 6.9–13.6). Overall CA-125 response 
occurred in 12 patients (80.0%) with 50% response, 8 patients (53.3%) with 75% response, 
and 10 patients (66.7%) with complete normalization of CA-125. and no patient had a study 
remission length longer than the prior remission.
4. Discussion
While the standard treatment of platinum-sensitive EOC continues to be debulking surgery 
followed by paclitaxel/carboplatin, adding a third cytotoxic agent provided no improvement 
in either PFS or OS when investigated in a Phase 3 study of 4312 women with advanced 
stage EOC [18]. Recently, the combination of FAR plus carboplatin/taxane (paclitaxel or 
docetaxel) was associated with high response rates in patients with platinum-sensitive EOC 
at first relapse, based on results of a Phase 2 trial [7] and in a subset of patients in a 
subsequent placebo-controlled Phase 3 trial [19]. The Phase 2 study of the efficacy of FAR 
plus carboplatin/taxane found normalization of CA-125 in 80.9% of patients, an objective 
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response rate of 75%, as well as increased duration of the progression-free interval (relative 
to the first response interval) in 21% of evaluable patients [7].
Though for many years carboplatin/paclitaxel has been regarded as the treatment of choice 
at time of relapse for patients with platinum-sensitive disease, recent clinical trial data have 
emerged to support the use of carboplatin/gemcitabine or carboplatin/PLD as an alternative 
to carboplatin/paclitaxel in this setting [9–11,20]. Carboplatin/PLD appears to be better 
tolerated and includes the benefit of a slight improvement in PFS [9]. Additionally, there are 
some aspects of this regimen that may be preferred by patients, including the lack of 
propensity for alopecia and psychological implications of receiving a new regimen (rather 
than retreatment with the original regimen, which ultimately resulted in recurrence). The use 
of carboplatin/PLD has increased since the aforementioned trials of FAR plus carboplatin/
paclitaxel. In Europe, as well as in major academic centers in the US, a preference for 
carboplatin/PLD has evolved. However, in the US in general, a preference for carboplatin/
paclitaxel remains. Accordingly, to assess the feasibility of adding FAR to the 
carboplatin/PLD combination, we undertook the Phase 1b safety study reported here in 
women with platinum-sensitive EOC. In this study, FAR in combination with 
carboplatin/PLD appeared to be generally well tolerated, with a safety profile consistent 
with that seen previously for FAR alone and in combination with the carboplatin/PLD 
regimen, where no additive toxicity was found [7]. The majority of AEs were those expected 
with the carboplatin/PLD combination chemotherapy backbone, including neutropenia and 
PPE. Compared with 103 chemotherapy-related AEs, there were 11 AEs that were 
considered by the investigators to be at least possibly FAR-related, the most common being 
constipation and fatigue at 2 reports each; however high-dose (10 mg/kg weekly) single-
agent FAR did not show similar effects [21]. Although farletuzumab may be associated with 
fatigue, the incidence of fatigue in this study was low compared with the ~40% reported in 
other carboplatin/PLD studies [9,11]. No clinical safety concerns were noted after the 
maintenance dose was modified, from FAR 2.5 mg/kg every 4 weeks to 7.5 mg/kg every 3 
weeks, per the protocol amendment. Although the efficacy data reported here are 
preliminary, given that this was a Phase 1b safety study, the CA-125 normalization rate of 
67% and objective response rate of 73% (11 of 15) are encouraging for this study patient, 
which included patients in second as well as first platinum-sensitive relapse.
This Phase 1b study assessed the safety and tolerability of FAR plus carboplatin/PLD as a 
first step toward the pursuit of this triple-agent regimen in future studies of EOC. Use of 
PLD as a replacement for paclitaxel, specifically in the context of FAR, is also of interest, 
given observations of immunosuppressive effects for paclitaxel in an ovarian cell line 
(stemming from an observed interference with interleukin-2-mediated immune system 
activation) [22], which could potentially interfere with the immune-mediated mechanism of 
actions of FAR; however, the clinical relevance of these preclinical findings is uncertain. 
Nonetheless, in view of increased use of carboplatin/PLD in the platinum-sensitive EOC 
population, additional investigation of this combination plus a third agent appears warranted. 
Formal assessment of efficacy was not feasible given the study limitation of sample size in 
this Phase 1 study. As supported by the favorable safety data described here, a randomized, 
placebo-controlled Phase 2 study is planned (MORAb-003-011 [NCT02289950]) to assess 
the efficacy of FAR in combination with carboplatin/PLD or carboplatin/paclitaxel (per 
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investigator choice) in patients with platinum-sensitive EOC (low CA-125 at ≤3× upper 
limit of normal) at first relapse, with PFS as the primary endpoint.
In conclusion, we found that when FAR was combined with carboplatin/PLD for the 
treatment of platinum-sensitive EOC, the safety profile was consistent with that of the 
doublet of carboplatin/PLD. Further evaluation of FAR/carboplatin/PLD is underway.
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HIGHLIGHTS
• Farletuzumab (FAR), a monoclonal antibody to folate receptor alpha, which is 
expressed in epithelial ovarian cancer (EOC).
• FAR has shown activity against EOC in platinum-sensitive relapse when 
combined with carboplatin and a taxane.
• Carboplatin in combination with pegylated liposomal doxorubicin (PLD) is a 
frequently used alterative regimen.
• This safety study assessed the addition of FAR to carboplatin/PLD, with a view 
toward future larger studies.
• This combination was generally well tolerated; adverse event profile was similar 
to that of carboplatin/PLD alone.
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Fig. 1. 
Disposition of subjects across combination and maintenance treatment periods.
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Table 1
Patient demographics and baseline disease characteristics.
All subjects
(N = 15)
Age, median (range), years 62.0 (47–82)
Age group, n (%)
 18–< 65 years 10 (66.7)
 ≥65 years 5 (33.3)
Race white, n (%) 15 (100)
Ethnicity not Hispanic or Latino, n (%) 15 (100)
Karnofsky performance status, n (%)
 100% 3 (20.0)
 90% 12 (80.0)
Stage of disease, n (%)
 IIC 3 (20.0)
 IIIA 1 (6.7)
 IIIC 8 (53.3)
 IV 3 (20.0)
Histologic subtype, n (%)
 Serous 10 (66.7)
 Adenocarcinoma NOS 5 (33.3)
Primary site, n (%)
 Fallopian tube 1 (6.7)
 Ovary 14 (93.3)
Relapse, n (%)
 First relapse 12 (80)
 Second relapse 3 (20)
Length of first remission, a mean (SD), months 21.6 (13.47)
Length of first remission, a n (%), months
 6 to <12 6 (40.0)
 12 to <18 1 (6.7)
 18 to 24 3 (20.0)
 >24 5 (33.3)
a
Length of first remission is based on the platinum-based chemotherapy used prior to study entry and is defined as the period of time (in months) 
from the date of last dose of platinum-based chemotherapy until date of first relapse by RECIST or GCIG.
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Table 2
Treatment-related adverse events that occurred in more than one subject.
MedDRA system organ class/preferred terma FAR/carboplatin/PLD (N = 15)
FAR-related n (%)b Chemotherapy-related n (%)b
Blood and lymphatic system disorders
 Neutropenia 6 (40.0)
 Anemia 2 (13.3)
Gastrointestinal disorders
 Nausea 5 (33.3)
 Diarrhea 3 (20.0)
 Vomiting 3 (20.0)
 Constipation 2 (13.3) 2 (13.3)
General disorders and administration site conditions
 Fatigue 2 (13.3) 10 (66.7)
 Mucosal inflammation 3 (20.0)
Metabolism and nutrition disorders
 Decreased appetite 3 (20.0)
Musculoskeletal and connective tissue disorders
 Pain in extremity 2 (13.3)
Nervous system disorders
 Hypoesthesia 3 (20.0)
 Dysgeusia 2 (13.3)
 Neuropathy peripheral 2 (13.3)
Skin and subcutaneous tissue disorders
 Palmar-plantar erythrodysesthesia syndrome 5 (33.3)
 Rash 5 (33.3)
 Alopecia 4 (26.7)
FAR = farletuzumab, PLD = pegylated liposomal doxorubicin.
aSubjects may have more than one Preferred Term within a given System Organ Class.
b
For each Preferred Term: n = number of subjects; % = percentages are based on the number of subjects who received FAR/carboplatin/PLD.
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